CASI Pharmaceuticals Inc. (NASDAQ:CASI) price on Thursday, August 26, fall -1.90% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.55.
A look at the stock’s price movement, the close in the last trading session was $1.58, moving within a range at $1.47 and $1.60. The beta value (5-Year monthly) was 0.15. Turning to its 52-week performance, $3.90 and $1.13 were the 52-week high and 52-week low respectively. Overall, CASI moved 31.36% over the past month.
CASI Pharmaceuticals Inc.’s market cap currently stands at around $206.66 million, with investors looking forward to this quarter’s earnings report slated for Nov 08, 2021 – Nov 12, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.07, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.25 and about -$0.21 for fiscal year 2022. Per the data, EPS growth is expected to be 43.20% for 2021 and 16.00% for the next financial year.
Analysts have a consensus estimate of $7.16 million for the company’s revenue for the quarter, with a low and high estimate of $5.8 million and $6.2 million respectively. The average forecast suggests up to a 168.10% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $27.97 million, representing a 84.70% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that CASI is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend CASI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CASI’s current price about 21.81% and 14.07% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 63.69, while 7-day volatility ratio is 10.00% and 7.82% in the 30-day chart. Further, CASI Pharmaceuticals Inc. (CASI) has a beta value of 0.13, and an average true range (ATR) of 0.11. Analysts have given the company’s stock an average 52-week price target of $4.45, forecast between a low of $3.80 and high of $6.00. Looking at the price targets, the low is -145.16% off current price level while to achieve the yearly target high, price needs to move -287.1%. Nonetheless, investors will most likely welcome a -158.06% jump to $4.00 which is the analysts’ median price.
In the market, a comparison of CASI Pharmaceuticals Inc. (CASI) and its peers suggest the former has performed considerably weaker. Data shows CASI’s intraday price has changed -1.90% in last session and -12.43% over the past year. Comparatively, Fennec Pharmaceuticals Inc. (FENC) has moved -0.25% on the day and only 39.82% in the past 12 months. Looking at another peer, we see that Neurocrine Biosciences Inc. (NBIX) price has dipped -1.55% on the day. However, the stock is -16.53% off its price a year ago. Moreover, Cyclacel Pharmaceuticals Inc. (CYCC) is also up 3.52% in trading on the day while keeping a an uptrend of 29.90% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.58% and -0.54% respectively in the last trading.
If we refocus on CASI Pharmaceuticals Inc. (NASDAQ:CASI), historical trading data shows that trading volumes averaged 5.57 million over the past 10 days and 1.34 million over the past 3 months. The company’s latest data on shares outstanding shows there are 139.80 million shares.
The 3.40% of CASI Pharmaceuticals Inc.’s shares are in the hands of company insiders while institutional holders own 33.50% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.33 million on May 27, 2021, giving us a short ratio of 2.99. The data shows that as of May 27, 2021 short interest in CASI Pharmaceuticals Inc. (CASI) stood at 3.81% of shares outstanding, with shares short rising to 3.46 million registered in Apr 29, 2021. Current price change has pushed the stock -47.46% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CASI stock continues to rise going into the next quarter.